Related Experiment Video
Updated: May 22, 2026
11:17
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Update on a Pharmacokinetic-Centric Alternative Tier II Program for MMT-Part I: Program Implementation and Lessons
David C Dorman1, Melvin E Andersen, Jerry M Roper
1College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607, USA.
Journal of Toxicology
|May 1, 2012
Summary
This study developed physiologically based pharmacokinetic (PBPK) models for manganese, improving risk assessments for environmental manganese exposure. These models predict tissue manganese concentrations, considering various factors for better health evaluations.
Area of Science:
- Environmental Health
- Toxicology
- Pharmacokinetics
Background:
- Environmental manganese exposure is linked to neurological disorders.
- Previous risk assessments by the US EPA highlighted uncertainties in manganese pharmacokinetics.
- Regulatory requirements necessitated pharmacokinetic data for methylcyclopentadienyl manganese tricarbonyl (MMT) combustion products.
Purpose of the Study:
- To generate essential pharmacokinetic data for manganese, specifically from MMT.
- To develop physiologically based pharmacokinetic (PBPK) models for manganese.
- To enhance future risk assessments by incorporating tissue dosimetry.
Main Methods:
- Implementation of the Alternative Tier 2 testing program for MMT.
- Generation of substantial pharmacokinetic data for inorganic manganese.
- Development and validation of PBPK models for manganese.
Main Results:
- Acquisition of significant pharmacokinetic data for manganese.
- Successful development of PBPK models for manganese.
- Models demonstrate predictive capability for tissue manganese concentrations.
Conclusions:
- PBPK models enable prediction of tissue manganese levels across diverse exposure scenarios.
- Models account for age, gender, and reproductive status, crucial for accurate dosimetry.
- This work supports improved risk assessment for environmental manganese exposure.
Related Concept Videos
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
01:19Nonlinear Pharmacokinetics: Overview
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
01:06Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
01:14Model Approaches for Pharmacokinetic Data: Compartment Models
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
Two primary types of compartment models are recognized: mammillary and catenary. The more...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).